CS2 & CS12: Walk distance results

SPINRAZA® can alter disease progression in later-onset SMA1

  • With SPINRAZA®, 6MWT distance continued to improve in ambulatory patients over 3 years1
  • Two previously non-independent ambulatory patients (Type III) achieved independent walking, and one non-ambulatory patient (Type II) achieved independent walking1

Change in 6MWT distance1

Scheme
Scheme
Banner
Banner

Lauren
age 20 years*
Later-onset (Type III) SMA
treated with SPINRAZA®

*Age at time of photo shoot.

References:
1. SPINRAZA® Summary of Product Characteristics.